TickerGuard
Buy Day today: Neutral (54) Mixed market breadth · no major macro event
CRLBF

Cresco Labs Inc.

Healthcare · Drug Manufacturers - Specialty & Generic

0.63$ -6.0% vs. previous close Closing price · As of: Oct 5, 2026

Statements

Ratios

Valuation ratios (P/E, P/S, EV/EBITDA and the other multiples) are based on the closing price at the end of each period, not on the current price. Margins and returns are shown in percent, multiples without a unit, per-share figures in the reporting currency, net debt in millions.

Tick rows to compare them in a chart (up to 4)

Ratios CRLBF
Line item Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26
Valuation
0.9 0.6 0.9 0.7 0.8 0.4 0.4 0.3 0.7 0.7 0.5 0.5
1.3 0.9 1.4 1.2 1.3 0.7 0.6 0.4 1.1 1.3 1.0 0.9
1.4 1.1 1.4 1.3 1.3 0.9 0.7 0.6 1.1 1.2 1.1 1.1
– – – – – – – – – – 39.4 50.3
12.9 8.9 9.0 7.7 7.9 2.9 2.5 2.1 10.7 12.4 – 66.5
7.7% 11.2% 11.1% 13.0% 12.6% 34.2% 40.1% 48.2% 9.4% 8.0% -1.3% 1.5%
Margins
45.2% 47.0% 48.5% 50.4% 51.1% 50.3% 49.7% 49.5% 48.5% 49.5% 50.1% 49.9%
4.2% 8.2% 11.6% 14.8% 15.9% 15.2% 13.4% 12.8% 11.8% 11.7% 11.6% 9.6%
-43.6% -23.0% -20.3% -23.1% -9.2% -10.3% -11.9% -6.7% -7.8% -20.6% -20.9% -15.5%
6.7% 6.9% 10.5% 9.6% 10.1% 15.0% 14.5% 12.8% 6.5% 5.3% -0.7% 0.7%
Returns
-67.4% -35.1% -30.7% -36.9% -14.8% -15.7% -18.1% -10.3% -12.2% -39.8% -39.9% -28.1%
-24.4% -13.1% -11.4% -12.7% -4.9% -5.5% -6.1% -3.4% -4.1% -11.3% -11.2% -8.0%
Balance Sheet & Debt
383 394 375 386 346 323 215 225 281 359 386 387
– – – – – – – – – – 21.5 28.0
36.2% 37.2% 37.0% 34.4% 33.0% 35.0% 33.9% 33.0% 33.5% 28.4% 28.0% 28.4%
1.0 1.0 1.0 1.1 1.1 1.0 0.8 0.8 0.8 1.2 1.2 1.2
Per Share
-1.01 -0.52 -0.45 -0.50 -0.19 -0.21 -0.24 -0.13 -0.15 -0.38 -0.36 -0.27
2.32 2.27 2.22 2.15 2.12 2.08 2.00 1.93 1.88 1.82 1.73 1.75
1.50 1.49 1.47 1.35 1.31 1.36 1.31 1.25 1.20 0.95 0.91 0.96
0.15 0.16 0.23 0.21 0.21 0.31 0.29 0.25 0.12 0.10 -0.01 0.01

Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?